INVO Bioscience, Inc. Logo

INVO Bioscience, Inc.

INVO

(1.8)
Stock Price

0,83 USD

-83.67% ROA

0% ROE

-0.34x PER

Market Cap.

2.626.832,00 USD

210.49% DER

0% Yield

0% NPM

INVO Bioscience, Inc. Stock Analysis

INVO Bioscience, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

INVO Bioscience, Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (3240.99%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 PBV

The stock's low PBV ratio (-0x) suggests it's undervalued, making it an attractive opportunity for investors.

3 DER

The stock has a low debt to equity ratio (-301%), which means it has a small amount of debt compared to the ownership it holds

4 Graham Number

The Graham number analysis indicates that this company's stock price is likely undervalued, raising prospects for a favorable investment opportunity.

5 ROA

The stock's ROA (-159.56%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

8 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

9 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (-274) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

INVO Bioscience, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

INVO Bioscience, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

INVO Bioscience, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

INVO Bioscience, Inc. Revenue
Year Revenue Growth
2006 0
2007 0 0%
2008 37.995 100%
2009 63.204 39.89%
2010 67.648 6.57%
2011 71.503 5.39%
2012 56.377 -26.83%
2013 27.063 -108.32%
2014 16.588 -63.15%
2015 11.689 -41.91%
2016 50.901 77.04%
2017 282.145 81.96%
2018 494.375 42.93%
2019 1.480.213 66.6%
2020 1.037.286 -42.7%
2021 4.160.116 75.07%
2022 822.196 -405.98%
2023 3.899.576 78.92%
2023 3.020.575 -29.1%
2024 7.346.388 58.88%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

INVO Bioscience, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2006 0
2007 0 0%
2008 51.761 100%
2009 7.650 -576.61%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 398.426 100%
2021 216.430 -84.09%
2022 544.043 60.22%
2023 10.672 -4997.85%
2023 165.945 93.57%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

INVO Bioscience, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2006 7.602
2007 43.466 82.51%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

INVO Bioscience, Inc. EBITDA
Year EBITDA Growth
2006 -1.602
2007 -24.800 93.54%
2008 -1.853.951 98.66%
2009 -1.828.699 -1.38%
2010 -1.501.338 -21.8%
2011 -681.773 -120.21%
2012 -540.789 -26.07%
2013 -593.723 8.92%
2014 -1.670.045 64.45%
2015 -589.441 -183.33%
2016 -2.108.536 72.05%
2017 -637.611 -230.69%
2018 -2.628.870 75.75%
2019 -1.788.092 -47.02%
2020 -5.510.776 67.55%
2021 -5.374.327 -2.54%
2022 -10.826.731 50.36%
2023 -3.495.796 -209.71%
2023 -6.626.531 47.25%
2024 -6.690.280 0.95%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

INVO Bioscience, Inc. Gross Profit
Year Gross Profit Growth
2006 0
2007 0 0%
2008 27.907 100%
2009 21.813 -27.94%
2010 45.820 52.39%
2011 53.591 14.5%
2012 35.497 -50.97%
2013 16.479 -115.41%
2014 8.906 -85.03%
2015 3.879 -129.6%
2016 35.807 89.17%
2017 230.191 84.44%
2018 404.008 43.02%
2019 1.340.543 69.86%
2020 948.526 -41.33%
2021 4.015.064 76.38%
2022 490.673 -718.28%
2023 1.575.704 68.86%
2023 1.086.138 -45.07%
2024 2.978.444 63.53%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

INVO Bioscience, Inc. Net Profit
Year Net Profit Growth
2006 -7.386
2007 -43.386 82.98%
2008 -1.873.405 97.68%
2009 -4.661.469 59.81%
2010 -153.430 -2938.17%
2011 -797.471 80.76%
2012 -666.454 -19.66%
2013 -760.679 12.39%
2014 -1.732.472 56.09%
2015 -4.959.247 65.07%
2016 -2.124.252 -133.46%
2017 -702.163 -202.53%
2018 -3.076.091 77.17%
2019 -2.167.544 -41.92%
2020 -8.347.316 74.03%
2021 -6.654.940 -25.43%
2022 -10.892.511 38.9%
2023 -4.993.760 -118.12%
2023 -8.034.612 37.85%
2024 -8.980.680 10.53%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

INVO Bioscience, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2006 0
2007 -1 0%
2008 -33 100%
2009 -55 40.74%
2010 -2 -5300%
2011 -6 83.33%
2012 -5 -20%
2013 -6 0%
2014 -13 61.54%
2015 -23 43.48%
2016 -10 -155.56%
2017 -3 -200%
2018 -13 75%
2019 -9 -50%
2020 -30 73.33%
2021 -13 -150%
2022 -18 29.41%
2023 -3 -750%
2023 -5 60%
2024 -2 -150%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

INVO Bioscience, Inc. Free Cashflow
Year Free Cashflow Growth
2006 -1.011
2007 -12.941 92.19%
2008 -1.140.504 98.87%
2009 -926.664 -23.08%
2010 -315.992 -193.26%
2011 -117.779 -168.29%
2012 -43.209 -172.58%
2013 -59.916 27.88%
2014 -19.401 -208.83%
2015 -151.622 87.2%
2016 -339.600 55.35%
2017 -181.270 -87.34%
2018 -672.371 73.04%
2019 1.255.807 153.54%
2020 -4.864.078 125.82%
2021 -6.484.563 24.99%
2022 -6.616.047 1.99%
2023 -1.355.528 -388.08%
2023 -5.199.776 73.93%
2024 -1.510.788 -244.18%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

INVO Bioscience, Inc. Operating Cashflow
Year Operating Cashflow Growth
2006 -1.011
2007 -12.941 92.19%
2008 -1.066.629 98.79%
2009 -926.664 -15.1%
2010 -315.992 -193.26%
2011 -117.779 -168.29%
2012 -43.209 -172.58%
2013 -59.916 27.88%
2014 -19.401 -208.83%
2015 -151.622 87.2%
2016 -323.900 53.19%
2017 -181.270 -78.68%
2018 -652.971 72.24%
2019 1.370.513 147.64%
2020 -4.775.148 128.7%
2021 -6.029.914 20.81%
2022 -6.603.319 8.68%
2023 -1.247.311 -429.4%
2023 -4.755.054 73.77%
2024 -1.455.657 -226.66%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

INVO Bioscience, Inc. Capital Expenditure
Year Capital Expenditure Growth
2006 0
2007 0 0%
2008 73.875 100%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 15.700 100%
2017 0 0%
2018 19.400 100%
2019 114.706 83.09%
2020 88.930 -28.98%
2021 454.649 80.44%
2022 12.728 -3472.04%
2023 108.217 88.24%
2023 444.722 75.67%
2024 55.131 -706.66%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

INVO Bioscience, Inc. Equity
Year Equity Growth
2006 37.539
2007 27.753 -35.26%
2008 -676.567 104.1%
2009 -3.237.137 79.1%
2010 -2.481.909 -30.43%
2011 -2.925.271 15.16%
2012 -3.372.699 13.27%
2013 -3.814.797 11.59%
2014 -4.358.969 12.48%
2015 -3.757.002 -16.02%
2016 -4.617.646 18.64%
2017 -4.992.112 7.5%
2018 -2.724.223 -83.25%
2019 -3.713.595 26.64%
2020 5.743.106 164.66%
2021 7.310.680 21.44%
2022 -977.612 847.81%
2023 372.799 362.24%
2023 892.825 58.25%
2024 1.363.516 34.52%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

INVO Bioscience, Inc. Assets
Year Assets Growth
2006 37.789
2007 29.982 -26.04%
2008 311.555 90.38%
2009 287.836 -8.24%
2010 180.996 -59.03%
2011 127.878 -41.54%
2012 125.269 -2.08%
2013 122.543 -2.22%
2014 108.051 -13.41%
2015 579.786 81.36%
2016 286.226 -102.56%
2017 266.413 -7.44%
2018 777.347 65.73%
2019 1.795.479 56.71%
2020 10.947.343 83.6%
2021 10.466.380 -4.6%
2022 4.103.715 -155.05%
2023 19.476.171 78.93%
2023 20.887.787 6.76%
2024 18.031.759 -15.84%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

INVO Bioscience, Inc. Liabilities
Year Liabilities Growth
2006 250
2007 2.229 88.78%
2008 988.122 99.77%
2009 3.524.973 71.97%
2010 2.662.905 -32.37%
2011 3.053.149 12.78%
2012 3.497.968 12.72%
2013 3.937.340 11.16%
2014 4.467.020 11.86%
2015 4.336.788 -3%
2016 4.903.872 11.56%
2017 5.258.525 6.74%
2018 3.501.570 -50.18%
2019 5.509.074 36.44%
2020 5.204.237 -5.86%
2021 3.155.700 -64.92%
2022 5.081.327 37.9%
2023 19.103.372 73.4%
2023 19.994.962 4.46%
2024 16.668.243 -19.96%

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

INVO Bioscience, Inc. Dividends
Year Dividends Growth

INVO Bioscience, Inc. Profile

About INVO Bioscience, Inc.

INVO Bioscience, Inc., a commercial-stage fertility company, provides assisted reproductive technology solutions worldwide. Its flagship product is the INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The company was founded in 2007 and is based in Sarasota, Florida.

CEO
Mr. Steven M. Shum
Employee
25
Address
5582 Broadcast Court
Sarasota, 34240

INVO Bioscience, Inc. Executives & BODs

INVO Bioscience, Inc. Executives & BODs
# Name Age
1 Ms. Terah Krigsvold
Controller
70
2 Mr. Robert Joseph Bowdring Jr.
Treasurer & Secretary
70
3 Mr. Michael Jos. Campbell
Chief Operating Officer & Vice President of Business Development
70
4 Mr. Steven M. Shum
Chief Executive Officer & Director
70
5 Mr. Andrea Goren
Chief Financial Officer
70
6 Mr. Bojan Mitrovic Ph.D.
Director of Sales US
70

INVO Bioscience, Inc. Competitors